ADoBind MC001 / Medicovestor - LARVOL DELTA

FDA Grants Orphan Drug Designation to Medicovestor’s First-in-Class ADC for Pancreatic Cancer (GlobeNewswire) - "Medicovestor, Inc...announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ADoBind MC001, its lead candidate for the treatment of pancreatic cancer....Medicovestor is currently progressing ADoBind MC001 through IND-enabling studies, with a Phase 1 clinical trial expected to begin in early 2026."

New P1 trial • Orphan drug • Pancreatic Cancer